Early intervention with second‐generation antipsychotics in first‐episode psychosis: results of an 8‐week naturalistic study

Josiassen, Richard C.; Shaughnessy, Rita A.; Filymer, Dawn M.; Donohue, Ann Marie; Kacso, Margit; Finkel, Naomi; Curtis, Jessica; Audino, Brett; Skuban, Nina

doi:10.1111/j.1751-7893.2010.00163.x

Cited by 13 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The total number of patients in these studies was 4139 (2594 male, 1545 female). Five studies were double blinded, [32][33][34][35][36] one was single blinded, 37 and 22 were open label. 20,24,31,[38][39][40][41][42][43][44][45][46][47][48][49][50][51][52] Of these 28 studies, 12 (42.8%) were funded by pharmaceutical companies, 6 (21.4%) were funded by institutional or government agencies, and 3 (10.7%) were funded by pharmaceutical companies and institutional agencies.…”

Section: Resultsmentioning

confidence: 99%

Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications

Tek

Küçükgöncü

Gülöksüz

et al. 2016

FOC

View full text Add to dashboard Cite

Aim-The first-episode psychosis (FEP) represents a critical period to prevent cardiovascular and metabolic morbidity decades later. Antipsychotic (AP)-induced weight gain is one modifiable factor in this period. The purpose of this study is to conduct a meta-analysis of AP-induced weight and body mass index (BMI) change in FEP.Methods-A comprehensive literature search identified 28 articles that reported data on APspecific weight or BMI change in FEP. We conducted a meta-analysis of short-and long-term mean weight and BMI differences between placebo and AP medications. We also performed subgroup and meta-regression analysis to examine weight, BMI outcomes and their relationship with location (Asian vs. Western), sponsorship and baseline weight and BMIs.Results-Compared to placebo, AP-caused mean weight gain was 3.22 kg and 1.4 points BMI in the short-term, and 5.30 kg and 1.86 points BMI in the long term. Clinically significant weight gain risk increased about twofold with AP use. Weight gain was associated with duration of AP use. AP medications were associated with more weight gain in Western samples as opposed to Asian samples. Most AP medications were associated with significant body weight gain and BMI increase in FEP patients, except for ziprasidone. Olanzapine and clozapine caused the highest weight gain compared to placebo.Conclusion-Except for ziprasidone, most AP medications were associated with body weight gain and BMI increase in FEP patients. Early and continuing effects of various AP medications on weight gain and BMI increase should be taken into consideration by clinicians.

show abstract

Section: Resultsmentioning

confidence: 99%

Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications

Tek

Küçükgöncü

Gülöksüz

et al. 2016

FOC

View full text Add to dashboard Cite

show abstract

“…For the short-term meta-analysis, 39 weight change outcomes were extracted from 21 unique intervention studies 20,31-35,37-47,51-54 and 23 BMI change outcomes from 11 unique samples. 20,33,37,41,42,44,[51][52][53][54][55] Nine of these studies lasted less than 12 weeks. 32,37,[39][40][41][45][46][47]52 Weight change From analysis of the selected studies, the overall mean weight gain difference between AP medications and placebo was 3.22 kg (CI = 1.65-4.80, P < 0.001).…”

Section: Short-term Results (≤12 Weeks)mentioning

confidence: 99%

Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications

Tek

Küçükgöncü

Gülöksüz

et al. 2015

Early Intervention Psych

145

View full text Add to dashboard Cite

Aim The first-episode psychosis (FEP) represents a critical period to prevent cardiovascular and metabolic morbidity decades later. Antipsychotic (AP)-induced weight gain is one modifiable factor in this period. The purpose of this study is to conduct a meta-analysis of AP-induced weight and body mass index (BMI) change in FEP. Methods A comprehensive literature search identified 28 articles that reported data on AP-specific weight or BMI change in FEP. We conducted a meta-analysis of short- and long-term mean weight and BMI differences between placebo and AP medications. We also performed subgroup and meta-regression analysis to examine weight, BMI outcomes and their relationship with location (Asian vs. Western), sponsorship and baseline weight and BMIs. Results Compared to placebo, AP-caused mean weight gain was 3.22 kg and 1.4 points BMI in the short-term, and 5.30 kg and 1.86 points BMI in the long term. Clinically significant weight gain risk increased about twofold with AP use. Weight gain was associated with duration of AP use. AP medications were associated with more weight gain in Western samples as opposed to Asian samples. Most AP medications were associated with significant body weight gain and BMI increase in FEP patients, except for ziprasidone. Olanzapine and clozapine caused the highest weight gain compared to placebo. Conclusion Except for ziprasidone, most AP medications were associated with body weight gain and BMI increase in FEP patients. Early and continuing effects of various AP medications on weight gain and BMI increase should be taken into consideration by clinicians.

show abstract

“…For instance, it would be important to identify people at high risk or in the early stages of psychosis, given that preliminary data have suggested that low doses of atypical antipsychotics associated with psychosocial interventions may delay the onset of psychosis in some individuals [63], and that early treatment with atypical antipsychotics may reduce the risk of transition to psychosis [64]. In addition, psychosocial interventions such as cognitive behavioral therapy and family interventions as well as close monitoring may be safer, more acceptable and more effective for at least a subgroup of patients in the early stages of psychosis [65], whereas patients with severe psychopathology at onset may benefit from an early intervention with low doses of second-generation antipsychotics [66]. The role of psychotherapy in its different forms should be better investigated in relation to DUP/DUI, in order to detect potential differences in efficacy between medications and psychotherapy or even against combined treatments.…”

Section: Resultsmentioning

confidence: 99%

Can Long-Term Outcomes Be Improved by Shortening the Duration of Untreated Illness in Psychiatric Disorders? A Conceptual Framework

et al. 2012

View full text Add to dashboard Cite

The duration of untreated illness (DUI), meaning the latency to the pharmacological treatment, has been increasingly investigated in the last decade as a predictor of outcome across different psychiatric conditions, particularly in psychotic disorders. DUI is essentially computed by subtracting the age of onset of a specific disorder from the age at which the first adequate pharmacological treatment is administered. Assessment of the latency to treatment represents one of the first steps in planning early interventions. This review examines the role of the DUI in psychotic and affective disorders, focusing on neuropathological, epidemiologic, clinical and prognostic factors related to a longer latency to treatment. Through a Medline and Cochrane Library search, relevant studies up to June 2011 and other pertinent articles including meta-analyses, randomized controlled trials, naturalistic studies and clinical reviews were identified. Converging evidence indicates that a prolonged DUI negatively influences the outcome of first-episode psychosis and schizophrenia in different ways, and increasing data point toward a similar conclusion in affective disorders. Even though methodological limitations related to investigation of the DUI need to be considered, research and interventions aimed to reduce latency to treatments are object of increasing implementation worldwide. The assessment of the DUI represents one of the most important parameters to consider in this perspective, in order to quantify different latency to treatment in specific disorders and to plan related, targeted interventions.

show abstract

Early intervention with second‐generation antipsychotics in first‐episode psychosis: results of an 8‐week naturalistic study

Cited by 13 publications

References 26 publications

Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications

Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications

Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications

Can Long-Term Outcomes Be Improved by Shortening the Duration of Untreated Illness in Psychiatric Disorders? A Conceptual Framework

Contact Info

Product

Resources

About